Key result
Hydralazine initially lowers blood pressure by ~35 mmHg but induces tolerance and biventricular hypertrophy.
Why the study?
The effects of hydralazine on blood pressure, pressor mechanisms, and cardiac hypertrophy over time in 2-kidney, 1-clip hypertensive rats were not fully characterized.
Does hydralazine reduce blood pressure and affect cardiac hypertrophy in 2-kidney, 1-clip hypertensive rats?
Does hydralazine reduce blood pressure and affect cardiac hypertrophy in 2-kidney, 1-clip hypertensive rats?
In a hypertensive rat model, hydralazine initially lowers blood pressure but leads to tolerance and induces right ventricular and eccentric left ventricular hypertrophy, likely driven by intravascular volume expansion and increased renin release.
Hydralazine tolerance and hypertrophy development caution against indefinite use; leaves open human translation and mechanisms.
In 2-kidney, 1-clip hypertensive rats, the time course of changes in blood pressure (BP), heart rate, activity of the sympathetic nervous system and the renin-angiotensin system, plasma and blood volumes, left ventricular (LV) and right ventricular (RV) weight, and LV dimensions were evaluated during treatment with hydralazine 80 and 120 mg/L drinking water for 2 days or 1, 2, 3, 5, and 8 weeks. Hydralazine induced initially a clear antihypertensive effect (mean BP from 170-180 down to 135-145 mmHg (1 mmHg = 133.32 Pa], subsequently tolerance developed. Heart rate, plasma catecholamines, and the blood pressure response to hexamethonium were not affected by treatment. Significant increases in plasma renin activity occurred during the initial 1-3 weeks of treatment. Plasma and blood volumes showed only small increases with prolonged treatment. RV weight and LV internal diameter showed significant increases at 3, 5, and 8 weeks of treatment, LV weight at 5 and 8 weeks. LV wall thickness did not change significantly. Thus, treatment with the arterial vasodilator hydralazine causes both RV hypertrophy and eccentric LV hypertrophy. Intravascular volume expansion, associated possibly with redistribution of blood volume to the central compartment, may play a major role in these cardiac effects. Increased renin release but not a generalized increase in sympathetic tone may play a role in the development of tolerance to the antihypertensive effect.
No takes yet. Share an insight, caveat, or question.
Tsoporis et al. (1986) studied 2-kidney, 1-clip hypertension. Hydralazine was evaluated on Blood pressure, heart rate, sympathetic/renin-angiotensin activity, volumes, and ventricular dimensions. Hydralazine initially reduced mean blood pressure from 170-180 to 135-145 mmHg in hypertensive rats, but tolerance developed, accompanied by right and eccentric left ventricular hypertrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: